…
23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
| Income before tax | -314.43M | -220.97M | -183.62M | -250.86M | - |
| Net income | -311.66M | -217.49M | -183.36M | -289.31M | - |
| Selling general administrative | 115.98M | 97.38M | 99.15M | 59.39M | - |
| Selling and marketing expenses | 119.93M | 100.34M | 43.20M | 110.52M | - |
| Gross profit | 134.50M | 132.94M | 117.01M | 137.43M | - |
| Reconciled depreciation | 36.50M | 26.15M | 20.25M | 23.29M | - |
| Ebit | -324.01M | -254.15M | -185.20M | -213.75M | -188.78M |
| Ebitda | -287.51M | -260.99M | -164.95M | -145.77M | - |
| Depreciation and amortization | 36.50M | -6.84M | 20.25M | 67.98M | - |
| Non operating income net other | -0.09M | 33.18M | - | - | - |
| Operating income | -324.01M | -254.15M | -185.20M | -213.75M | - |
| Other operating expenses | 623.50M | 526.05M | 429.12M | 519.22M | - |
| Interest expense | 9.58M | 0.28M | 1.58M | 6.24M | 0.00M |
| Tax provision | -2.77M | -3.48M | 0.00M | 0.00M | - |
| Interest income | 9.68M | - | 1.58M | - | - |
| Net interest income | 9.68M | 0.28M | 1.58M | 6.24M | - |
| Income tax expense | -2.77M | -3.48M | -0.26M | 38.45M | - |
| Total revenue | 299.49M | 271.89M | 243.92M | 305.46M | - |
| Total operating expenses | 458.51M | 387.10M | 302.20M | 351.19M | - |
| Cost of revenue | 164.99M | 138.95M | 126.91M | 168.03M | - |
| Total other income expense net | 9.58M | 33.18M | 1.58M | -37.11M | - |
| Net income from continuing ops | -311.66M | -217.49M | -183.62M | -250.86M | - |
| Net income applicable to common shares | -311.66M | -217.49M | -183.62M | -250.86M | -183.53M |
| Breakdown | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 |
| Total assets | 395.17M | 942.60M | 1152.07M | 452.10M | - |
| Intangible assets | - | 61.18M | 83.54M | 6.89M | - |
| Other current assets | 16.84M | 19.22M | 34.44M | 22.37M | 13.48M |
| Total liab | 206.65M | 228.66M | 236.41M | 1047.72M | - |
| Total stockholder equity | 188.52M | 713.94M | 915.66M | -595.62M | - |
| Other current liab | 42.26M | 66.43M | 44.59M | 31.95M | 84.75M |
| Common stock | 0.05M | 0.05M | 0.04M | 0.01M | - |
| Capital stock | - | 0.05M | 0.04M | 0.01M | - |
| Retained earnings | -2173.09M | -1506.38M | -1194.73M | -977.24M | -793.62M |
| Other liab | - | - | 4.65M | 1.17M | 48.27M |
| Good will | - | 351.74M | 351.74M | 0.00M | - |
| Other assets | 0.00M | 10.85M | 10.42M | 8.48M | 9.05M |
| Cash | 217.89M | 386.85M | 553.18M | 282.49M | - |
| Total current liabilities | 127.33M | 149.42M | 153.24M | 121.62M | 139.45M |
| Current deferred revenue | 64.83M | 62.52M | 62.94M | 71.25M | - |
| Net debt | -141.37M | -301.55M | -466.87M | -188.77M | - |
| Short term debt | 8.67M | 7.54M | 7.78M | 6.14M | - |
| Short long term debt total | 76.52M | 85.30M | 86.31M | 93.72M | - |
| Other stockholder equity | 2361.56M | 2220.90M | 2110.16M | 381.62M | - |
| Property plant equipment | - | 38.61M | 49.85M | 123.15M | 137.64M |
| Total current assets | 250.52M | 424.99M | 601.79M | 313.57M | 252.52M |
| Net tangible assets | - | 301.01M | 480.37M | -602.51M | -626.30M |
| Short term investments | - | - | - | 508.65M | - |
| Net receivables | 3.32M | 1.90M | 3.38M | 2.48M | 6.39M |
| Inventory | 12.46M | 10.25M | 10.79M | 6.24M | 14.12M |
| Accounts payable | 11.57M | 12.92M | 37.93M | 12.27M | 13.09M |
| Accumulated other comprehensive income | - | -0.62M | 0.18M | -50.33M | - |
| Common stock total equity | - | 0.05M | 0.04M | 487.05M | - |
| Retained earnings total equity | - | -1506.38M | -1194.73M | -48.60M | - |
| Non currrent assets other | 60.43M | 9.99M | 9.57M | 7.63M | - |
| Non current assets total | 144.65M | 517.61M | 550.28M | 138.52M | - |
| Capital lease obligations | - | 85.30M | 86.31M | 93.72M | - |
| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
| Investments | -11.30M | -108.14M | -6.54M | -72.82M | - |
| Change to liabilities | -25.48M | 18.74M | -16.07M | -65.14M | 20.79M |
| Total cashflows from investing activities | -11.30M | -108.14M | -6.54M | -72.82M | -27.84M |
| Total cash from financing activities | 9.78M | 546.00M | 155.34M | 8.83M | 344.45M |
| Change to operating activities | - | -9.41M | 5.79M | 25.13M | 8.60M |
| Net income | -311.66M | -217.49M | -183.62M | -250.86M | -183.53M |
| Change in cash | -166.53M | 270.89M | 74.55M | -249.76M | 218.49M |
| Begin period cash flow | 561.75M | 290.86M | 216.31M | 466.07M | - |
| End period cash flow | 395.22M | 561.75M | 290.86M | 216.31M | 466.07M |
| Total cash from operating activities | -165.39M | -166.83M | -74.25M | -185.77M | -98.12M |
| Issuance of capital stock | 0.00M | 309.72M | 82.50M | 0.00M | - |
| Depreciation | 36.50M | 26.15M | 20.25M | 23.29M | 9.90M |
| Other cashflows from investing activities | -7.26M | -104.17M | - | - | - |
| Change to inventory | 0.54M | -4.26M | 7.88M | -0.44M | 12.52M |
| Change to account receivables | 1.48M | -0.90M | 3.91M | 4.21M | -3.89M |
| Sale purchase of stock | 6.46M | 576.65M | - | - | - |
| Other cashflows from financing activities | 3.31M | 236.28M | 155.34M | -72.82M | -0.39M |
| Change to netincome | 126.22M | 25.03M | 88.11M | 78.80M | 37.49M |
| Capital expenditures | 11.30M | 13.97M | 7.37M | 73.59M | 27.40M |
| Change receivables | 1.48M | -0.90M | - | - | - |
| Cash flows other operating | 11.44M | -11.64M | - | - | - |
| Exchange rate changes | - | -0.15M | - | - | - |
| Cash and cash equivalents changes | -166.92M | 270.89M | - | - | - |
| Change in working capital | -16.45M | -0.52M | 1.51M | -36.25M | - |
| Stock based compensation | 116.02M | 57.93M | 88.42M | 44.84M | - |
| Other non cash items | 10.20M | -32.90M | -0.88M | 33.22M | - |
| Free cash flow | -176.69M | -180.80M | -81.63M | -259.35M | - |
Sector: Healthcare Industry: Diagnostics & Research
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| TMO Thermo Fisher Scientific Inc |
0.78 0.11% |
700.22 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
0.86 0.37% |
233.02 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| WUXIF WuXi AppTec Co. Ltd |
- -% |
24.91 | 22.29 | 17.95 | 1.53 | 5.98 | 8.39 | 14.30 |
| WUXAY WuXi AppTec Co. Ltd |
-0.17 0.68% |
24.93 | 23.28 | 18.73 | 1.51 | 6.24 | 8.39 | 14.30 |
23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.
349 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
650 938 6300
| Name | Title | Year Born |
|---|---|---|
| Ms. Anne Wojcicki | Co-Founder, CEO, Pres & Director | NA |
| Ms. Kathy L. Hibbs Esq., J.D. | Chief Admin. Officer and Sec. | 1964 |
| Dr. Kenneth J. Hillan Ch.B., M.B. | Chief Therapeutics Officer | 1961 |
| Mr. Joseph Selsavage | Interim CFO & Accounting Officer | 1963 |
| Dr. Joseph R. Arron M.D., Ph.D. | Chief Scientific Officer | NA |
| Dr. Wade Walke | VP of Investor Relations | 1966 |
| Ms. Jacquie Cooke Haggarty J.D. | Gen. Counsel & Privacy Officer | NA |
| Ms. Katie Watson | VP of Communications | 1978 |
| Mr. Jonathan Ward | Chief Marketing Officer | NA |
| Ms. Savita Pillai | VP of People | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.